3DT Holdings, LLC
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $935K has been obligated and $896K paid out. $38K has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$02
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
3DT HOLDINGS, LLC — Grant R43HL174201
LOW PROFILE TRANSCATHETER AORTIC VALVE IMPLANT - ABSTRACT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) IS GRADUALLY BECOMING AN ESSENTIAL ALTERNATIVE TO SURGICAL AORTIC VALVE REPLACEMENT (SAVR) FOR PATIENTS WITH SEVERE AORTIC STENOSIS (AS) AT HIGH OR PROHIBITIVE SURGICAL RISK. THE PUBLISHED PARTNER 3 AND EVOLUT LOW-RISK TRIALS HAVE RECENTLY DEMONSTRATED THAT TAVR CAN BE CONSIDERED IN LOW-RISK PATIENTS. HOWEVER, THE LONG-TERM DURABILITY OF TRANSCATHETER PROSTHETIC VALVES HAS BECOME A MAJOR CONCERN NOWADAYS, ESPECIALLY FOR YOUNG PATIENTS WITH GREATER LIFE EXPECTANCY. ALTHOUGH INCREASED EFFICACY AND SAFETY OF THE CURRENT LEADING TAVR VALVES (E.G., MEDTRONIC COREVALVE AND EDWARDS SAPIEN) HAVE BEEN REPORTED LATELY, TISSUE VALVE DYSFUNCTION AND FAILURE REMAIN THE LIMITING FACTORS FOR THE LONG-TERM OUTCOME OF TAVR. FURTHERMORE, THE APPLICATION OF THOSE TAVR VALVES IS LIMITED TO CERTAIN PATIENTS DUE TO THE USE OF THE RELATIVELY LARGE DELIVERY SYSTEM (TYPICALLY 14-16 FR. SIZE). THERE IS A SUBS
Timeline
No timeline articles for this company yet.